Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Basal Cell Nevus Syndrome 2Skin Neoplasms 1Pancreatic Diseases 1Multiple Myeloma 1Medulloblastoma 1Hematologic Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Basal Cell 1Carcinoma 1

Interventions

Carboplatin 7Pemetrexed 5pembrolizumab 4Gemcitabine 4osimertinib 3Sorafenib 3Paclitaxel 3Interleukin-2 3Cyclophosphamide 3Cisplatin 3seocalcitol 2selinexor 2patritumab 2liposomal doxorubicin 2interferon gamma-1b 2fludarabine 2Sunitinib 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Irinotecan 2Erlotinib Hydrochloride 2DNA 2Celecoxib 2Capecitabine 2Bleomycin 2Bevacizumab 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2volociximab 1thioredoxin reductase inhibitor AM12 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma × sonidegib × Clear all
NCT01431794 2020-01-22

Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Terminated
23 enrolled 10 charts
Gastrointestinal

Carcinoma, Pancreatic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡